The authors compared the outcomes of two-stage, acellular dermal matrix (AlloDerm)-assisted prosthetic breast reconstruction including different timings of radiotherapy. Methods: A review of two-stage, AlloDerm-assisted, prosthetic breast reconstructions from 2004 to 2010 was performed. All data were recorded prospectively and the study population was stratified by the timing of radiotherapy. Complications were analyzed following first-and second-stage reconstruction. The Spear-Baker classification of capsular contracture was modified for irradiated devices. Reconstructive failure was defined as nonelective removal of a breast prosthesis. Results: AlloDerm-assisted prosthetic reconstruction was performed in 289 women (428 breasts). After first-stage reconstruction, clinically significant capsular contracture rates (grade III/IV) were higher in the radiation therapy during expansion group and in the radiation therapy before mastectomy group compared with the no-radiation therapy group. Three hundred fiftythree breasts (85.9 percent) successfully underwent second-stage reconstruction, with a median follow-up of 15.2 months. Of those 353 breasts, clinically significant capsular contracture (grade III/IV) was highest in the radiation therapy during expansion group. More often than in the other groups, the radiation therapy during expansion group failed two-stage reconstruction and required flaps in addition or as replacement. Conclusions: In AlloDerm-assisted prosthetic breast reconstruction, irradiated devices demonstrated higher rates of clinically significant capsular contracture following the first stage. These rates declined considerably on completion of reconstruction, with prostheses irradiated during expansion still having the highest frequency of clinically significant capsular contracture. With the follow-up reported, irradiated devices failed breast reconstruction less frequently and required autologous tissue less often than has been historically reported without acellular dermal matrix. (Plast. Reconstr. Surg. 130: 1, 2012.) CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
percent hematoma rate, a 0.0 to 9.0 percent seroma rate, and a 0.0 to 14.0 percent rate of explantation caused by exposure. 20 Despite the increasing amount of data regarding acellular dermal matrix-assisted prosthetic breast reconstructions, specific data regarding the incidence of capsular contracture and outcomes in the presence of radiation therapy are less welldocumented. The purpose of this study was to compare the outcomes of two-stage, AlloDermassisted, prosthetic breast reconstruction in the setting of different timings of radiotherapy, with a particular focus on rates of clinically significant capsular contracture, need for flap intervention, and frequency of failed two-stage reconstruction.
PATIENTS AND METHODS

Study Design and Population
An institutional review board-approved review was carried out on all patients who had twostage immediate prosthetic breast reconstruction using AlloDerm from August of 2004 to June of 2010. There were 289 women identified representing the practice of the two senior surgeons (S.L.S. and M.Y.N.). Exclusion criteria consisted of patients who received delayed breast reconstruction or direct-to-implant breast reconstruction. Given the low number of cases of radiation therapy with an implant in place (n ϭ 5), this group was also excluded from the study.
Surgical Technique
In the setting of total mastectomy, all patients were offered two-stage prosthetic breast reconstruction using AlloDerm. There were no specific qualifying criteria, irrespective of a patient's irradiation status. Indeed, patients who were facing postmastectomy radiation therapy were offered the option of expander reconstruction at the time of the mastectomy.
The technique of two-stage AlloDerm-assisted prosthetic breast reconstruction has been described previously by the senior author (S.L.S.). 8 Salient aspects of the operation include orienting the AlloDerm with the dermal surface up against the mastectomy skin, suturing the AlloDerm to the chest wall defining the inframammary fold and lateral mammary fold, total or nearly total coverage of the device with pectoralis major muscle and AlloDerm, intraoperative expansion sufficient to eliminate ripples or folds in the AlloDerm, and placement of closed suction drains anterior and posterior to the AlloDerm. Drains are left in place until the output is less than 30 ml over a 24-hour period. Generally, patients are discharged on postoperative day 1. Oral antibiotics were continued until all drains were removed.
Serial expansion of the tissue expander was initiated on confirmation of normal incisional healing that typically commenced at 2 to 3 weeks. Patients were seen at weekly intervals until the desired fill volume was achieved. Expansion was generally completed before the initiation of radiation therapy. The tissue expander was not deflated before irradiation; however, further expansion ceased following the radiotherapy simulation markings. Chemotherapy was usually not a deterrent to expansion and was administered before, during, or after expander placement. After completion of tissue expansion and all adjuvant therapy, patients were scheduled for the second stage of the reconstruction. This usually included exchange of the expander for an implant and other interventions that included capsular modification, fat grafting, flap assistance, and/or conversion to autologous reconstruction. On average, secondstage breast reconstruction was performed 6 weeks after completion of chemotherapy. This was the general timeline, with the exception of irradiated patients, because the irradiation followed 6 weeks after the completion of chemotherapy. A minimum of 6 weeks was then allotted from the time of completion of radiotherapy to the second stage of reconstruction.
Data Collection and Analysis
Data from office and hospital records were collected. Associated demographics included patient age, body mass index, former or active tobacco use, and history of neoadjuvant or adjuvant chemotherapy. The study population was stratified by the timing of radiotherapy as follows: no radiation therapy, radiation therapy before mastectomy, and radiation therapy during expansion.
Number and types of complications were analyzed following first-and second-stage reconstruction and included exposure, hematoma, seroma, flap necrosis, infection, capsular contracture, operative management of infection/exposure, and elective explantation. After second-stage reconstruction, an additional outcome of interest was the need for implant-related revision secondary to capsular contracture, infection/exposure, and/or malposition. Patients with a follow-up period less than 6 months were excluded from outcomes analysis after secondstage prosthetic breast reconstruction. A modified version of the Spear-Baker classification 21 Operative management of capsular contracture, infection/exposure, and elective explantation was further categorized. Treatment of capsular contracture was subdivided into capsular modification, flap in addition, or flap as replacement. Operative management of infection/exposure was classified into device salvage (by capsular modification or flap in addition), explantation without salvage attempted, or explantation with flap as replacement. Management following elective explantation was subdivided into flap as replacement or no further reconstruction.
Late outcomes of interest included the success or failure of two-stage reconstruction and the need for flap in addition to or as replacement for prosthetic breast reconstruction. Success was defined as the presence of a breast prosthesis at the completion of the reconstruction. Failure was defined as nonelective removal of a breast prosthesis.
Statistical analyses were completed using the t test for comparison of parametric continuous variables, Fisher's exact test or chi-square analysis for evaluation of percentages or frequencies, and Kruskal-Wallis for comparison of nonparametric continuous values. A value of p Ͻ 0.05 was considered significant.
RESULTS
Over a 7-year period, 289 patients underwent AlloDerm-assisted prosthetic breast reconstruction. Patient demographics are summarized in Table 1. The mean age of the patients was 46.1 years, with a range of 23 to 70 years, and the mean body mass index was 24.4. Among 428 breasts, 355 (82.9 percent) underwent no radiation therapy, 17 (4.0 percent) received radiation therapy before mastectomy, and 56 (13.1 percent) underwent radiation therapy with an expander in place. All patients in the radiation therapy before mastectomy group had undergone radiation therapy as part of local control following breast conservation therapy. In addition, 14.5 percent had a history of neoadjuvant chemotherapy and 30.6 percent received postoperative chemotherapy. A history of tobacco use was demonstrated in women that included 11.7 percent of breasts.
The patients were further subdivided and compared between breast prostheses in the setting of different timings of radiotherapy (Table 2) . Comparison revealed no statistically significant differences in patient age, body mass index, or smoking history. Preoperative chemotherapy was significantly more common in those receiving radiation therapy with an expander in place versus those receiving radiation therapy before mastectomy or no radiation therapy (30.4 percent versus 5.9 percent versus 12.4 percent, p ϭ 0.001). Postoperative chemotherapy was also significantly more common in those receiving radiation therapy with an expander in place versus the radiation therapy before mastectomy group or the no-radiation therapy group (64.3 percent versus 29.4 percent versus 25.4 percent, p Ͻ 0.0001).
Outcomes following first-stage reconstruction of all 428 breasts were evaluated (Table 3) XRT, radiation therapy.
Volume 130, Number 1 • AlloDerm-Assisted Breast Reconstruction 26 breast devices (6.1 percent) were explanted. Fifteen prostheses (3.5 percent) were explanted secondary to infection/exposure, all but one with no salvage attempted. Eleven devices were explanted electively (2.6 percent), with nine receiving a flap as replacement and two undergoing no further reconstruction. Of the 46 breasts with clinically significant capsular contracture (grade III/ IV), 33 were managed with capsular modification (71.7 percent), eight received a flap as replacement (17.4 percent), two had a flap in addition (4.3 percent), and one underwent elective device explantation (2.2 percent) at the second stage (Table 4) .
Complications following first-stage reconstruction were then compared between breast prostheses in the setting of different timings of radiotherapy (Table 5 ). Frequencies of exposure, hematoma, seroma, flap necrosis, infection, device salvage, and explantation electively or because of infection/exposure were equivalent across the three groups. Rates of clinically significant capsular contracture (grade III/IV) were highest in the radiation therapy during expansion and radiation therapy before mastectomy groups compared with the no-radiation therapy group (60.7 percent versus 41.2 percent versus 1.4 percent, p Ͻ 0.0001).
Operative management of grade III/IV capsular contractures at the second stage, stratified by setting of radiotherapy, can be found in Table 6 . Of the five no-radiation therapy breasts with clinically significant contracture, one (20 percent) had correction with capsular modification, two (40 percent) had flaps as replacement, one (20 percent) had the expander removed, and one (20 percent) has an operation pending. Of the seven radiation therapy before mastectomy breasts with clinically significant contracture, all seven (100 percent) had a capsule modification (e.g., capsulotomy, capsulectomy, and/or addition of more AlloDerm at the exchange procedure). Of the 34 breasts with radiation therapy during expansion with clinically significant capsular contracture, 25 (73.5 percent) had a capsule modification procedure, six (17.6 percent) had a flap as replacement, two (5.9 percent) had a flap in addition, and one (2.9 percent) has an operation pending; none were simply explanted.
The overall intervention rate by capsular modification or flaps at the second stage for breasts irradiated with an expander in place, with or without capsular contracture, was 58.9 percent. Intervention by capsule modification occurred in 25 of 56 (44.6 percent) breasts irradiated with an ex- Plastic and Reconstructive Surgery • July 2012 pander in place. Nonelective flap intervention occurred in a total of eight of 56 (14.3 percent) breasts irradiated with an expander. Three hundred seventy-eight breasts underwent the second stage of breast reconstruction. Seventeen breasts were excluded secondary to follow-up less than 6 months, bringing the total to 361 breasts followed for a median of 15.2 months (range, 6.0 to 80.5 months). As shown in Table 7 , after the second stage, there were 35 grade IIB/ III/IV capsular contractures (9.7 percent), seven infections (1.9 percent), and six devices with exposure (1.7 percent). Four devices (1.1 percent) were successfully salvaged in the setting of infection/exposure, all by capsular modification. A total of seven implants (1.9 percent) were explanted secondary to infection/exposure, all but one with no salvage attempted. There were 29 implantrelated revisions subsequent to the exchange procedure as an additional operation (8.0 percent). Of the 15 breasts with clinically significant capsular contracture (grade III/IV), nine have intervention planned and pending (60.0 percent), five were managed with capsular modification (33.3 percent), and one received a flap as replacement (6.7 percent) at the third stage (Table 8) .
Outcomes following second-stage reconstruction were then compared between breast prostheses in the setting of different timings of radiotherapy (Table 9 ). Complications were uniformly higher in the irradiated groups (radiation therapy before mastectomy and radiation therapy during expansion) as compared with the nonirradiated Volume 130, Number 1 • AlloDerm-Assisted Breast Reconstruction group. Rates of clinically significant capsular contracture and implant-related revisions were highest in the radiation therapy during expansion group as compared with the radiation therapy before mastectomy and the no-radiation therapy groups (capsular contracture: 12.5 percent versus 6.7 percent versus 2.9 percent, p ϭ 0.02; revision: 17.5 percent versus 13.3 percent versus 6.5 percent, p ϭ 0.04, respectively).
Operative management of implant-related revisions at the third stage was stratified by the setting of radiotherapy. Of the 20 implant-related revisions in breasts with no radiation therapy, four (20.0 percent) were for capsular contracture, three (15.0 percent) were for infection/exposure, and 13 (65.0 percent) were for malposition. Of the two implant-related revisions in breasts with radiation therapy before mastectomy, both (100 percent) were for infection/exposure. Also, of the seven implant-related revisions in breasts with radiation therapy during expansion, one (14.3 percent) was for capsular contracture and six (85.7 percent) were for infection/exposure.
Late results after two-stage AlloDerm-assisted prosthetic breast reconstructions were then reviewed. Of the 411 breasts in which two-stage prosthetic reconstruction was initiated and with adequate follow-up, 353 breasts (85.9 percent) successfully underwent the reconstructive process with an implant in place. These breasts were further stratified based on the setting of radiation therapy (Table 10) . Nonirradiated breasts successfully underwent two-stage prosthetic reconstruction more often than the radiation therapy before mastectomy and radiation therapy during expansion groups (89.9 percent versus 76.5 percent versus 64.3 percent, p Ͻ 0.0001). Conversely, the radiation therapy during expansion group failed twostage reconstruction and required flaps in addition to or as replacement more often than the radiation therapy before mastectomy and no-radiation therapy groups (failure: 21.4 percent versus 11.8 percent versus 5.0 percent, p Ͻ 0.0001; flap required: 16.1 percent versus 5.9 percent versus 0.9 percent, p Ͻ 0.0001, respectively).
DISCUSSION
Ideally, any given article on acellular dermal matrix-assisted prosthetic breast reconstruction would report data specific to several important variables. Two of the more important variables are (1) the presence of breast radiation and (2) whether a tissue expander was used or whether this was an attempt at a one-stage procedure using an implant directly. Reports that do not include irradiated breasts will necessarily be reporting lower complication rates than reports that include them. This is borne out by the abundant literature that describes significantly more complications in any type of reconstruction of the irradiated breast. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The most valuable reports would be those that include both irradiated and nonirradiated breasts but that go on to segregate the data based on the timing of breast irradiation. The same is true regarding two-stage breast reconstruction with tissue expanders as opposed to one-stage direct-to-implant reconstruction.
As we prepared to review and discuss our experience with AlloDerm, some additional issues became apparent. The first is how best to report infection. Because infection can sometimes be difficult to diagnose with certainty, there needs to be an unambiguous benchmark by which to document infection. Skin flaps can turn pink or red because of ischemia, allergic reactions, irradiation, and infection, and after the fact, it is often uncertain which one it was. Thus, documenting and recording explantations caused by infection or exposure brings objectivity and clarity to that uncertainty.
A similar issue is measuring capsular contracture. The commonly used Baker classification was developed by James Baker for evaluating breast augmentation. 35 Although imperfect, its simplicity has helped it withstand the test of time. However, it was never intended as a measure of breast reconstruction because virtually all implant-based breast reconstructions, even perfect ones, have implants that are visible and are easily palpable, making them a minimum Baker grade III, which implies a bad outcome. Previously we modified the Baker system for reconstruction and created the category IB, which describes a soft, attractive, unencapsulated result where the implant is nevertheless visible and palpable. 21 Things become more complex when evaluating irradiated breasts because, generally speaking, irradiation virtually always produces fibrosis and some degree of tightening of the skin, tissues, and capsule around the implant. By analogy, if an explant is the best measure of a significant infection, then we propose that a surgical intervention is the best measure of a clinically significant capsular contracture after breast reconstruction. Such intervention could include a capsulotomy, capsulectomy, addition of more acellular tissue matrix material, adding a flap, or replacing the implant with an autologous reconstruction altogether. For the firm but clinically acceptable implant reconstruction (whether irradiated or not), which does not require a surgical intervention, we propose the Baker classification IIB to describe an implant that is visible, readily palpable, firmer than ideal or than the opposite implant (in the case of a bilateral implant reconstruction), but does not merit a surgical correction. The alternative of trying to score the results subjectively using the original Baker classification seems more imprecise and prone to inconsistency.
With these benchmarks defined, we compared outcomes of two-stage, AlloDerm-assisted, prosthetic breast reconstruction including different timings of radiotherapy. One of the principal findings of this study was the increased rate of clinically significant capsular contracture, whether following the first or second stage of reconstruction, in irradiated breasts as compared with nonirradiated breasts. This is in agreement with the prior literature on prosthetic breast reconstruction without acellular dermal matrix in the setting of irradiation. In a 12-year experience with tissue expander/implant breast reconstruction, Cordeiro and McCarthy found increased rates of Baker grade III/IV capsular contracture in breasts irradiated with an implant in place in comparison with nonirradiated breasts (50.7 percent versus 10.3 percent, respectively). 26 Similarly, in a report of 40 consecutive patients undergoing two-stage prosthetic breast reconstruction, Spear and Onyewu reported a 32.5 percent rate of symptomatic capsular contracture in irradiated breasts as compared with a 0.0 percent rate in nonirradiated breasts. 33 Second, we found that the timing of irradiation played a significant role in the severity of capsular contracture. Breasts irradiated with an expander in place had the highest rates of clinically significant contracture following either stage of the reconstruction. These findings are in agreement with the recently reported observations of Nava et al. 36 In their study of patients undergoing two-stage prosthetic breast reconstruction without acellular dermal matrix, Nava and colleagues noted that patients who received radiotherapy Lastly, irradiated devices failed breast reconstruction less frequently and required autologous tissue less often than historically reported without acellular dermal matrix. Our total failure rate of 21.4 percent in patients irradiated with an expander in place compared favorably with the historical rates of failure reported for this same irradiated cohort without the use of acellular dermal matrix. As recently as 2011, Nava and colleagues reported a 40 percent failure rate in patients undergoing two-stage prosthetic breast reconstruction without acellular dermal matrix and irradiation with an expander in place. 36 The total nonelective rate of flap use in addition to or as replacement for the prosthetic breast reconstruction was also relatively low for breasts irradiated with an expander in place or before mastectomy, at 16.1 percent and 5.9 percent, respectively. This was an improvement over the 30 percent nonelective rate of flap use reported by Spear and Onyewu in irradiated breasts that underwent two-stage prosthetic breast reconstruction without acellular dermal matrix.
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CONCLUSIONS
In AlloDerm-assisted prosthetic breast reconstruction, irradiated devices demonstrated high rates of clinically significant capsular contracture following the first stage. These rates declined considerably on completion of reconstruction, with prostheses irradiated during expansion mainly exhibiting clinically significant capsular contracture. With the follow-up reported in the current study, irradiated devices failed breast reconstruction less frequently and required autologous tissue less often than historically reported for irradiated prostheses undergoing partial submuscular coverage alone.
